Korro Bio (KRRO)
NASDAQ:KRRO
Top Page
Korro Bio
(NASDAQ:KRRO)
Select Model
Select Model
Rating:50Neutral
Price Target:
$14.00
▲(1.52% Upside)
Action:ReiteratedDate:04/04/26
The score is held down primarily by very weak financial performance (large ongoing losses, heavy cash burn, and reduced equity cushion). Partly offsetting this are improved near-term technical momentum and a supportive financing event that extends the cash runway, though pipeline setbacks temper the corporate-event benefit. Valuation remains constrained by unprofitability and lack of dividend support.
Positive Factors
Extended funding runway
The oversubscribed $85M PIPE plus year-end cash materially lengthens Korro's runway into H2 2028, lowering near-term refinancing pressure. This durable funding cushion lets management advance multiple clinical programs to value-inflecting milestones without immediate reliance on dilutive financing, supporting multi-quarter R&D execution.
Negative Factors
Heavy cash burn
Sustained operating and free cash flow deficits near $79M annually indicate the business cannot self-fund development. Over several quarters this ongoing burn will necessitate fresh capital or program curtailment; dependence on markets increases dilution and execution risk if clinical timelines slip or financing conditions worsen.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended funding runway
The oversubscribed $85M PIPE plus year-end cash materially lengthens Korro's runway into H2 2028, lowering near-term refinancing pressure. This durable funding cushion lets management advance multiple clinical programs to value-inflecting milestones without immediate reliance on dilutive financing, supporting multi-quarter R&D execution.
Read all positive factors
Korro Bio (KRRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$194.13M
Dividend YieldN/A
Average Volume (3M)734.66K
Price to Earnings (P/E)―
Beta (1Y)2.68
Revenue GrowthN/A
EPS Growth21.61%
CountryUS
Employees112
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.33
Shares Outstanding14,422,571
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue23.18
Enterprise Value/Gross Profit25.80
Enterprise Value/Ebitda-1.81
Forecast
1Y Price Target
$19.75Price Target Upside43.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-8.05
Revenue Forecast (FY)$2.20M
Korro Bio Business Overview & Revenue Model
Company Description
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts....
How the Company Makes Money
Korro Bio generates revenue primarily through research collaborations, licensing agreements, and upfront payments from strategic partnerships with pharmaceutical companies. These agreements often include milestone-based payments tied to the progre...
Korro Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.39M | 2.27M | 0.00 | 0.00 | 14.07M |
| Gross Profit | 2.11M | 2.27M | 0.00 | 0.00 | 10.23M |
| EBITDA | -83.06M | -88.34M | -80.90M | -56.49M | -80.07M |
| Net Income | -117.26M | -83.58M | -81.17M | -58.03M | -84.69M |
Balance Sheet | |||||
| Total Assets | 113.51M | 226.24M | 221.66M | 73.74M | 185.36M |
| Cash, Cash Equivalents and Short-Term Investments | 75.16M | 126.09M | 166.15M | 55.85M | 130.71M |
| Total Debt | 43.49M | 44.77M | 33.21M | 166.99M | 45.60M |
| Total Liabilities | 62.07M | 65.83M | 51.75M | 172.77M | 54.53M |
| Stockholders Equity | 51.44M | 160.41M | 169.91M | -99.03M | 130.82M |
Cash Flow | |||||
| Free Cash Flow | -79.08M | -77.98M | -75.12M | -58.86M | -36.54M |
| Operating Cash Flow | -78.56M | -60.07M | -67.28M | -53.65M | -32.09M |
| Investing Cash Flow | 43.99M | -123.35M | 11.16M | 11.06M | -39.50M |
| Financing Cash Flow | 685.00K | 69.36M | 187.76M | 18.00K | 115.94M |
Korro Bio Technical Analysis
Positive
13.79
Price Trends
11.87
Positive
10.03
Positive
18.64
Negative
Market Momentum
0.50
Negative
60.82
Neutral
67.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRRO, the sentiment is Positive. The current price of 13.79 is above the 20-day moving average (MA) of 11.88, above the 50-day MA of 11.87, and below the 200-day MA of 18.64, indicating a neutral trend. The MACD of 0.50 indicates Negative momentum. The RSI at 60.82 is Neutral, neither overbought nor oversold. The STOCH value of 67.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRRO.
Korro Bio Risk Analysis
Korro Bio disclosed 89 risk factors in its most recent earnings report. Korro Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Korro Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $515.62M | -3.10 | -47.27% | ― | ― | ― | |
52 Neutral | $781.39M | -7.71 | -32.72% | ― | ― | -40.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $194.13M | -0.38 | -115.95% | ― | ― | 21.61% | |
49 Neutral | $970.87M | -3.77 | -101.33% | ― | ― | -35.62% | |
48 Neutral | $434.30M | -3.10 | -71.25% | ― | ― | -11.41% | |
45 Neutral | $465.57M | -62.28 | -5.63% | ― | 31.30% | 32.79% |
* Healthcare Sector Average
KRRO
Korro Bio
13.46
0.49
3.78%
ASMB
Assembly Biosciences
29.35
20.89
246.93%
ANNX
Annexon Biosciences
6.05
4.67
338.41%
FDMT
4D Molecular Therapeutics
10.10
7.51
289.96%
DSGN
Design Therapeutics
12.67
9.88
354.12%
AURA
Aura Biosciences Inc
6.77
1.80
36.22%
Korro Bio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Korro Bio Announces Oversubscribed $85M PIPE Financing
Positive
Mar 9, 2026
On March 9, 2026, Korro Bio entered into a subscription agreement for an oversubscribed private investment in public equity, selling common shares and pre-funded warrants to institutional investors for expected gross proceeds of about $85 million,...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Korro Bio Showcases KRRO-121 RNA Editing Program Progress
Positive
Jan 27, 2026
On January 27, 2026, Korro Bio, Inc. held a virtual Analyst Day where management presented KRRO-121, a GalNAc-conjugated antisense oligonucleotide designed to edit glutamine synthetase (GS) mRNA in the liver, creating a more stable GS variant to e...
Business Operations and StrategyProduct-Related Announcements
Korro Bio Updates Pipeline, Terminates KRRO-110 REWRITE Trial
Negative
Jan 15, 2026
On January 15, 2026, Korro Bio, Inc. updated its corporate presentation for investors and analysts, outlining a pipeline that includes KRRO-121 for hyperammonemia progressing toward a planned regulatory filing in the second half of 2026, an AATD G...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.